Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03946878|
Recruitment Status : Recruiting
First Posted : May 13, 2019
Last Update Posted : August 22, 2019
|Condition or disease||Intervention/treatment||Phase|
|Blastoid Variant Mantle Cell Lymphoma CCND1 Protein Overexpression CD20 Positive CD5 Positive FCER2 Negative Pleomorphic Variant Mantle Cell Lymphoma Recurrent Mantle Cell Lymphoma Refractory Mantle Cell Lymphoma t(11;14)(q13;q32)||Drug: Acalabrutinib Drug: Venetoclax||Phase 2|
I. To evaluate the efficacy of a combination of venetoclax and acalabrutinib, in patients with previously treated relapsed/refractory mantle cell lymphoma (MCL).
I. To evaluate the efficacy of this combination regimen in previously treated subjects with relapsed/refractory MCL with overall response rate (ORR), duration of response (DOR), event free survival (EFS), progression free survival (PFS), and overall survival (OS).
II. To evaluate the safety and tolerability of venetoclax and acalabrutinib in previously treated subjects with relapsed/refractory MCL.
CORRELATIVE/TRANSLATIONAL COMPONENT OBJECTIVES:
I. Sequential peripheral blood (PB)/plasma/tissue fine needle aspirate will be stored.
II. Clonal evolution with targeted sequencing (seq) and/or whole exome sequencing (WES) in sequential samples.
III. Pattern of mutation changes with Bruton tyrosine kinase inhibitor (BTKi) or with venetoclax resistance.
IV. Response predictors - mutations, cytokine-chemokines, clonal evolution (CE).
V. Minimal residual disease (MRD) assay using circulating tumor deoxyribonucleic acid (ctDNA) analysis, flow cytometry at various time points from peripheral blood (PB)/ bone marrow (BM).
VI. Sequential immunologic studies with cytokines/chemokines, T cell numbers, and immunoglobulins (Ig).
VII. Tissue microenvironmental studies with simultaneous assessment of PB, BM and lymph nodes for gene expression profiling (GEP), single cell seq, ribonucleic acid (RNA) seq and clonal heterogeneity and the impact of acalabrutinib - venetoclax (A-V) treatment.
OUTLINE: This is a dose escalation study of venetoclax.
Patients receive acalabrutinib orally (PO) twice daily (BID) on days 1-28. Starting cycle 2 day 1, patients also receive venetoclax PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up within 30 days, then every 4 months for 2 years, then every 6 months for the next 2 years, and then annually thereafter.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label, Phase II Investigator Initiated Study of Venetoclax and Acalabrutinib in Previously Treated Relapsed/Refractory Patients With Mantle Cell Lymphoma (MCL)|
|Actual Study Start Date :||August 13, 2019|
|Estimated Primary Completion Date :||February 8, 2024|
|Estimated Study Completion Date :||February 8, 2024|
Experimental: Treatment (acalabrutinib, venetoclax)
Patients receive acalabrutinib PO BID on days 1-28. Starting cycle 2 day 1, patients also receive venetoclax PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- Complete response (CR) [ Time Frame: 16 weeks ]Assessed by Lugano criteria - positron emission tomography (PET)-computed tomography, and in a subset of patients by bone marrow flow cytometry, circulating tumor deoxyribonucleic acid and endoscopy if at baseline there is gut involvement. Response will be calculated separately with and without knowledge of the PET result by International Working Group criteria, in order to provide context in relation to historical control data. Will estimate the CR along with the 95% credible interval.
- Overall response rate [ Time Frame: 5 years ]
- Duration of response [ Time Frame: 5 years ]Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test.
- Event free survival [ Time Frame: 5 years ]Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test.
- Progression free survival [ Time Frame: 5 years ]Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test.
- Overall survival [ Time Frame: 5 years ]
- Incidence of adverse events [ Time Frame: 5 years ]Safety data will be summarized by frequency tables for all patients. Per-treated analysis will be performed to include any patient who received the treatment regardless of the eligibility nor the duration or dose of the treatment received.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03946878
|Contact: Luhua (Michael) Wang, MD,MSfirstname.lastname@example.org|
|Contact: Preetesh Jain, MD,DM, PHDemail@example.com|
|United States, Texas|
|M D Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Luhua (Michael) Wang, MD,MS 713-792-2860|
|Contact: Preetesh Jain, MD,DM,PhD 713-745-8432|
|Principal Investigator: Luhua (Michael) Wang|
|Principal Investigator:||Luhua (Michael) Wang||M.D. Anderson Cancer Center|